Dr. Quentin Zimmermann

Allergist · Universitätsklinikum Heidelberg · Germany (DE) · Immunology

Tier 2STK-0155GoodOwner MSL RARachel Adeyemi

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Inflammatory skin disease
Disease interests: AD
Scientific interests: Adolescent ADLong-term safetyJAK selectivity
Engagement preference: Either
Advisory boards: 0
Publications: 49
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 2: 2 per year (assumption)

Last engaged: 01 Jun 2026 (106 days ago)
Next planned contact: 01 Dec 2026
Last 6 months vs target: 100%
1 of 1 expected engagements

Insights from this stakeholder (0)

No insights captured from engagements with this stakeholder.

Engagement history (2)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
01 Jun 2026	Scientific exchange	In person	Rachel Adeyemi	Aurelin	Phase IIb efficacyAdolescent population+1	0	—	Reviewed	ENG-0239
06 Mar 2026	Investigator meeting	In person	Rachel Adeyemi	Aurelin	Long-term safety monitoring	0	Compliance	Reviewed	ENG-0228

Timeline

01 Jun 2026
Scientific exchange
Phase IIb efficacy, Adolescent population, JAK1/TYK2 selectivity
06 Mar 2026
Investigator meeting
Long-term safety monitoring

Related stakeholders (8)

Universitätsklinikum Heidelberg

Dr. Chloé Rossi
Pathologist
Tier 3
Dr. Andrea Castellano
Thoracic medical oncologist
Tier 3
Dr. William Abbott
Radiation oncologist
Tier 3
Dr. Sven Eriksen
Academic nephrologist
Tier 2
Dr. Benedikt Vogel
Community nephrologist
Tier 1
Dr. Benedikt Xu
Academic nephrologist
Tier 2
Dr. Tomoko Xu
Primary care physician
Tier 1
Dr. Andrea Ivanova
Allergist
Tier 3